Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

Documenti analoghi

• New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2011)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2011)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  di: Chaft, Jamie E., et al.
  Pubblicazione: (2011)
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
  di: Yu, Helena A., et al.
  Pubblicazione: (2015)
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
  di: Yu, Helena A., et al.
  Pubblicazione: (2013)